Dr. Leath is the Ellen Gregg Shook Culverhouse Chair in Gynecologic Oncology, a Tenured Full Professor, and Division Director at the University of Alabama at Birmingham. Following medical school, he completed both residency in Obstetrics and Gynecology and fellowship in Gynecologic Oncology at the University of Alabama at Birmingham. Currently Dr. Leath is the Chair of the NRG Oncology Cervical & Vulvar Cancer Committee and a former member of the Safety Committee and is the National Principal Investigator for NRG clinical trial GY006 evaluating the addition of triapine to standard chemoradiation for locally advanced cervical cancer. Dr. Leath is board certified in both Obstetrics & Gynecology and Gynecologic Oncology and holds a Masters of Science in Public Health (MSPH) degree from the University of Alabama School of Public Health. In addition to being a member of the National Comprehensive Cancer Center (NCCN) Ovarian Cancer Guidelines, he is one of the Discussion writing committee members.
He is the institutional principal investigator for the Lead Academic Participating Site (LAPS) grant as part of the National Cancer Institutes’ National Clinical Trial Network, the Chair of the O’Neal Comprehensive Cancer Center Protocol Review and Monitoring Committee and is an investigator on the combined Johns Hopkins-UAB Cervical Cancer SPORE. Dr. Leath is actively involved in clinical research in the management of cervical, endometrial and ovarian cancers, as well as clinical trials for all aspects of gynecologic cancer, and is an author or co-author of over 160 peer-reviewed publications.